RALEIGH, N.C., U.S.A. (March 29, 2007)

 Qualyst, Inc., a leader in the development and marketing of novel and proprietary absorption, distribution, metabolism, excretion and toxicology (ADMET) technologies, today announced that orders are now being accepted for B-CLEAR® Kits using rat hepatocytes. 

 B-CLEAR® is a proprietary, patented system that provides for the in vitro assessment and in vivo prediction of hepatobiliary disposition, hepatic uptake, hepatic accumulation, biliary clearance and drug transport. B-CLEAR® supplies organizations with decision making information, in critical areas related to hepatic transport and adverse drug interactions, by generating physiologically-relevant data helping to avoid costly drug development challenges.

“Qualyst is excited to provide clients access to B‑CLEAR® through their consumables budgets, simplifying and broadening access to the valuable data B‑CLEAR® can provide,” said Dr. Ian Mehr, Qualyst vice president of business development.  “Each B-CLEAR® Kit manufactured by Qualyst will contain plates of B-CLEAR® hepatocytes, media, buffers and instructions for multiple research applications.” 

About Qualyst, Inc.
Qualyst commercializes novel and proprietary ADMET products for drug discovery and development. Qualystís products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process. Qualyst, Inc. was founded on discoveries from breakthrough research at the University of North Carolina at Chapel Hill in 2001. For additional information, please refer to the company's web site at www.Qualyst.com or call 919-313-6500.

CONTACT:

Ian J. Mehr
Vice President, Business Development
Qualyst, Inc.
919-313-6507
info[AT]qualyst[DOT]com
www.Qualyst.com